Hematologic oncology and related blood disorders are some of the most rapidly evolving fields in all of medicine. Results presented at major conferences from a plethora of ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care, the practicing hematologist-oncologist must be well informed of these advances. To bridge the gap between research and patient care, this issue of Cancer Conference Update uses one-on-one discussions with Drs Flowers, Fonseca, Kahl, Kantarjian and Talpaz about the integration of key data sets presented at the 2013 American Society of Hematology Annual Meeting into the practical management of a number of hematologic cancers and related blood disorders.
LEARNING OBJECTIVES
- Apply emerging clinical research data to the rational selection of treatment for patients with various hematologic cancers.
- Summarize emerging data with novel agents and combination approaches for newly diagnosed or relapsed/refractory indolent or aggressive B-cell non-Hodgkin lymphomas.
- Appraise the efficacy of the antibody-drug conjugate brentuximab vedotin in CD30-positive cutaneous T-cell lymphoma.
- Appreciate the recent FDA approvals of obinutuzumab and ibrutinib, and discern how these agents can be optimally integrated into clinical practice for patients with chronic lymphocytic leukemia.
- Recognize and apply clinical advances in the treatment of Hodgkin lymphoma.
- Evaluate recent clinical research information on the use of approved and investigational JAK2 inhibitors for patients with myelofibrosis, and apply this information to the protocol and off-protocol care of these individuals.
- Compare and contrast the benefits and risks of approved first- and second-generation tyrosine kinase inhibitors as therapeutic options for patients with chronic myeloid leukemia.
- Establish an understanding of emerging efficacy and side-effect data with novel agents and combination regimens under evaluation for multiple myeloma and Waldenström macroglobulinemia and, where appropriate, facilitate patient access to ongoing trials of these agents.
- Assess novel agents and treatment strategies for acute leukemias.
CME credit is no longer available for this issue
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
This CME activity contains an audio component. The participant should listen to the audio MP3s.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
Dr Talpaz — Advisory Committee: ARIAD Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi; Consulting Agreement: Pfizer Inc; Contracted Research: Abbott Laboratories, ARIAD Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Pfizer Inc, Sanofi. Dr Flowers — Advisory Committee: Biogen Idec, Genentech BioOncology, Roche Laboratories Inc; Consulting Agreements: Algeta ASA, Celgene Corporation, OptumRx Inc; Contracted Research: Abbott Laboratories, Celgene Corporation, Millennium: The Takeda Oncology Company, Spectrum Pharmaceuticals Inc.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology/Biogen Idec, Incyte Corporation and Onyx Pharmaceuticals Inc.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: April 2014
Expiration date: April 2015